Pharmacy World and Science

, Volume 17, Issue 1, pp 12-16

First online:

Selective digestive decontamination in multiple trauma patients: Cost and efficacy

  • A. Langlois-KaragaAffiliated withPharmacy, Hôpital Nord
  • , M. Bues-CharbitAffiliated withPharmacy, Hôpital Nord
  • , A. DavignonAffiliated withPharmacy, Hôpital Nord
  • , J. AlbaneseAffiliated withIntensive Care Unit, Hôpital Nord
  • , O. DurbecAffiliated withIntensive Care Unit, Hôpital Nord
  • , C. MartinAffiliated withIntensive Care Unit, Hôpital Nord
  • , N. MoratiAffiliated withMedical Information Unit, Hôpital Nord
  • , G. BalansardAffiliated withPharmacy, Hôpital Nord

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A double-blind randomized placebo-controlled study was carried out to evaluate the efficacy and the cost of selective digestive decontamination (SDD) to prevent nosocomial pneumonia in multiple-trauma patients. Nosocomial infections, particularly pneumonia, were more frequent in the placebo group. The most common infectious agent wasStaphylococcus: Staphylococcus aureus in the placebo group andStaphylococcus epidermidis in the SDD group. Methicillin-resistantStaphylococcus epidermidis was detected more often in the SDD group. No methicillin-resistantStaphylococcus aureus was observed in this study. Fewer patients in the SDD group required antibiotherapy. SDD resulted in a saving of about 41% in drug expenditure.


Antibiotics Bacteria Clinical trials Costs and cost analysis Drug utilization Infection Multiple trauma Selective digestive decontamination